Management algorithm for HIV-associated parotid lymphoepithelial cysts

Waleed F. Mourad, Shyamal Patel, Rebekah Young, Azita S. Khorsandi, Catherine Concert, Rania A. Shourbaji, Katherine Ciarrocca, Richard L. Bakst, Daniel Shasha, Chandan Guha, Madhur K. Garg, Kenneth S. Hu, Shalom Kalnicki, Louis B. Harrison

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report an evidence-based management algorithm for benign lymphoepithelial cysts (BLEC) of the parotid glands in HIV patients based on long-term outcomes after radiation therapy. From 1987 to 2013, 72 HIV-positive patients with BLEC of the parotid glands treated at our institutions were identified and their medical records were reviewed and analyzed. The primary endpoint of our study was to determine a dose response in HIV patients with BLEC. In group A (≤18 Gy), which received a median dose of 10 Gy (8–18), overall response (OvR), complete response (CR), partial response (PR), and local failure (LF) was experienced by 7, 7, 0, and 93 %, respectively. In group B (≥22.5 Gy), which received a median dose of 24 Gy (22.5–30), OvR, CR, PR, and LF was experienced by 88, 65, 23, and 12 %. Logistic regression revealed that higher dose (≥22.5 Gy) predicted for cosmetic control (p = 0.0003). Multiple regression analysis revealed higher dose predicted for cosmetic control (p = 0.0001) after adjusting for confounding variables (age, gender, race, HAART use, BLEC duration, and fractionation size). No patients in either group experienced RTOG grade ≥3 toxicities. A radiation dose of 24 Gy delivered in 12–16 fractions of 1.5–2 Gy per fraction provides long-term cosmetic control in HIV-positive patients with BLEC of the parotid glands.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalEuropean Archives of Oto-Rhino-Laryngology
DOIs
StateAccepted/In press - Feb 16 2016

Fingerprint

Cysts
HIV
Parotid Gland
Cosmetics
Confounding Factors (Epidemiology)
Highly Active Antiretroviral Therapy
Medical Records
Radiotherapy
Logistic Models
Regression Analysis
Radiation

Keywords

  • AIDS
  • Benign lymphoepithelial cysts
  • HAART
  • HIV
  • Parotid gland
  • Radiation therapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Mourad, W. F., Patel, S., Young, R., Khorsandi, A. S., Concert, C., Shourbaji, R. A., ... Harrison, L. B. (Accepted/In press). Management algorithm for HIV-associated parotid lymphoepithelial cysts. European Archives of Oto-Rhino-Laryngology, 1-8. https://doi.org/10.1007/s00405-016-3926-4

Management algorithm for HIV-associated parotid lymphoepithelial cysts. / Mourad, Waleed F.; Patel, Shyamal; Young, Rebekah; Khorsandi, Azita S.; Concert, Catherine; Shourbaji, Rania A.; Ciarrocca, Katherine; Bakst, Richard L.; Shasha, Daniel; Guha, Chandan; Garg, Madhur K.; Hu, Kenneth S.; Kalnicki, Shalom; Harrison, Louis B.

In: European Archives of Oto-Rhino-Laryngology, 16.02.2016, p. 1-8.

Research output: Contribution to journalArticle

Mourad, WF, Patel, S, Young, R, Khorsandi, AS, Concert, C, Shourbaji, RA, Ciarrocca, K, Bakst, RL, Shasha, D, Guha, C, Garg, MK, Hu, KS, Kalnicki, S & Harrison, LB 2016, 'Management algorithm for HIV-associated parotid lymphoepithelial cysts', European Archives of Oto-Rhino-Laryngology, pp. 1-8. https://doi.org/10.1007/s00405-016-3926-4
Mourad, Waleed F. ; Patel, Shyamal ; Young, Rebekah ; Khorsandi, Azita S. ; Concert, Catherine ; Shourbaji, Rania A. ; Ciarrocca, Katherine ; Bakst, Richard L. ; Shasha, Daniel ; Guha, Chandan ; Garg, Madhur K. ; Hu, Kenneth S. ; Kalnicki, Shalom ; Harrison, Louis B. / Management algorithm for HIV-associated parotid lymphoepithelial cysts. In: European Archives of Oto-Rhino-Laryngology. 2016 ; pp. 1-8.
@article{e59a9ad926934b7f8379c99e11ec1384,
title = "Management algorithm for HIV-associated parotid lymphoepithelial cysts",
abstract = "We report an evidence-based management algorithm for benign lymphoepithelial cysts (BLEC) of the parotid glands in HIV patients based on long-term outcomes after radiation therapy. From 1987 to 2013, 72 HIV-positive patients with BLEC of the parotid glands treated at our institutions were identified and their medical records were reviewed and analyzed. The primary endpoint of our study was to determine a dose response in HIV patients with BLEC. In group A (≤18 Gy), which received a median dose of 10 Gy (8–18), overall response (OvR), complete response (CR), partial response (PR), and local failure (LF) was experienced by 7, 7, 0, and 93 {\%}, respectively. In group B (≥22.5 Gy), which received a median dose of 24 Gy (22.5–30), OvR, CR, PR, and LF was experienced by 88, 65, 23, and 12 {\%}. Logistic regression revealed that higher dose (≥22.5 Gy) predicted for cosmetic control (p = 0.0003). Multiple regression analysis revealed higher dose predicted for cosmetic control (p = 0.0001) after adjusting for confounding variables (age, gender, race, HAART use, BLEC duration, and fractionation size). No patients in either group experienced RTOG grade ≥3 toxicities. A radiation dose of 24 Gy delivered in 12–16 fractions of 1.5–2 Gy per fraction provides long-term cosmetic control in HIV-positive patients with BLEC of the parotid glands.",
keywords = "AIDS, Benign lymphoepithelial cysts, HAART, HIV, Parotid gland, Radiation therapy",
author = "Mourad, {Waleed F.} and Shyamal Patel and Rebekah Young and Khorsandi, {Azita S.} and Catherine Concert and Shourbaji, {Rania A.} and Katherine Ciarrocca and Bakst, {Richard L.} and Daniel Shasha and Chandan Guha and Garg, {Madhur K.} and Hu, {Kenneth S.} and Shalom Kalnicki and Harrison, {Louis B.}",
year = "2016",
month = "2",
day = "16",
doi = "10.1007/s00405-016-3926-4",
language = "English (US)",
pages = "1--8",
journal = "Archives of Otolaryngology",
issn = "2168-6181",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Management algorithm for HIV-associated parotid lymphoepithelial cysts

AU - Mourad, Waleed F.

AU - Patel, Shyamal

AU - Young, Rebekah

AU - Khorsandi, Azita S.

AU - Concert, Catherine

AU - Shourbaji, Rania A.

AU - Ciarrocca, Katherine

AU - Bakst, Richard L.

AU - Shasha, Daniel

AU - Guha, Chandan

AU - Garg, Madhur K.

AU - Hu, Kenneth S.

AU - Kalnicki, Shalom

AU - Harrison, Louis B.

PY - 2016/2/16

Y1 - 2016/2/16

N2 - We report an evidence-based management algorithm for benign lymphoepithelial cysts (BLEC) of the parotid glands in HIV patients based on long-term outcomes after radiation therapy. From 1987 to 2013, 72 HIV-positive patients with BLEC of the parotid glands treated at our institutions were identified and their medical records were reviewed and analyzed. The primary endpoint of our study was to determine a dose response in HIV patients with BLEC. In group A (≤18 Gy), which received a median dose of 10 Gy (8–18), overall response (OvR), complete response (CR), partial response (PR), and local failure (LF) was experienced by 7, 7, 0, and 93 %, respectively. In group B (≥22.5 Gy), which received a median dose of 24 Gy (22.5–30), OvR, CR, PR, and LF was experienced by 88, 65, 23, and 12 %. Logistic regression revealed that higher dose (≥22.5 Gy) predicted for cosmetic control (p = 0.0003). Multiple regression analysis revealed higher dose predicted for cosmetic control (p = 0.0001) after adjusting for confounding variables (age, gender, race, HAART use, BLEC duration, and fractionation size). No patients in either group experienced RTOG grade ≥3 toxicities. A radiation dose of 24 Gy delivered in 12–16 fractions of 1.5–2 Gy per fraction provides long-term cosmetic control in HIV-positive patients with BLEC of the parotid glands.

AB - We report an evidence-based management algorithm for benign lymphoepithelial cysts (BLEC) of the parotid glands in HIV patients based on long-term outcomes after radiation therapy. From 1987 to 2013, 72 HIV-positive patients with BLEC of the parotid glands treated at our institutions were identified and their medical records were reviewed and analyzed. The primary endpoint of our study was to determine a dose response in HIV patients with BLEC. In group A (≤18 Gy), which received a median dose of 10 Gy (8–18), overall response (OvR), complete response (CR), partial response (PR), and local failure (LF) was experienced by 7, 7, 0, and 93 %, respectively. In group B (≥22.5 Gy), which received a median dose of 24 Gy (22.5–30), OvR, CR, PR, and LF was experienced by 88, 65, 23, and 12 %. Logistic regression revealed that higher dose (≥22.5 Gy) predicted for cosmetic control (p = 0.0003). Multiple regression analysis revealed higher dose predicted for cosmetic control (p = 0.0001) after adjusting for confounding variables (age, gender, race, HAART use, BLEC duration, and fractionation size). No patients in either group experienced RTOG grade ≥3 toxicities. A radiation dose of 24 Gy delivered in 12–16 fractions of 1.5–2 Gy per fraction provides long-term cosmetic control in HIV-positive patients with BLEC of the parotid glands.

KW - AIDS

KW - Benign lymphoepithelial cysts

KW - HAART

KW - HIV

KW - Parotid gland

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84958258809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958258809&partnerID=8YFLogxK

U2 - 10.1007/s00405-016-3926-4

DO - 10.1007/s00405-016-3926-4

M3 - Article

C2 - 26879995

AN - SCOPUS:84958258809

SP - 1

EP - 8

JO - Archives of Otolaryngology

JF - Archives of Otolaryngology

SN - 2168-6181

ER -